Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in chronic cholestatic liver disease

Sitrin, Michael D.; Bengoa, J M

doi:10.1093/ajcn/46.6.1011

Cited by 51 publications

(28 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…These findings are consis-tent with results from clinical studies, which have found better absorption of 25OHD versus vitamin D in patients with fat malabsorption [41][42][43]. Also, in healthy subjects [43,44] and in patients with bone disease [45] 25OHD is absorbed better and faster than vitamin D.…”

Section: Bioavailability Homeostasis and Transportsupporting

confidence: 85%

Food Contents and Biological Activity of 25-Hydroxyvitamin D: A Vitamin D Metabolite to Be Reckoned With?

Ovesen

Brot

Jakobsen³

2003

Ann Nutr Metab

174

113

View full text Add to dashboard Cite

Only a limited number of foods naturally contain vitamin D such as fish, meat and offal, and eggs, and milk and dairy products. However, all these foods in addition contain the metabolite 25-hydroxyvitamin D (25OHD). From the few systematic studies which have been performed the food contents of 25OHD in animal foods are usually low but vary. Contents are typically very low in milk and fish (<0.1 µg/100 g), somewhat higher in meat and offal (0.2–0.4 µg/100 g) and up to 1 µg/100 g in egg yolk. It has been demonstrated that 25OHD is absorbed better and faster from the diet than native vitamin D and has metabolic effects of its own in regulating cell growth and calcium metabolism. Thus, the biological activity of 25OHD is greater than that of native vitamin D. However, there is as yet no consensus on the conversion factor that should be used for 25OHD to calculate vitamin D activity. Depending on the testing system used the factor varies from 1.5 to 5. If food contents and the higher potency of 25OHD are not included in dietary intake surveys, true vitamin D intake will be underestimated.

show abstract

Section: Bioavailability Homeostasis and Transportsupporting

confidence: 85%

Food Contents and Biological Activity of 25-Hydroxyvitamin D: A Vitamin D Metabolite to Be Reckoned With?

Ovesen

Brot

Jakobsen³

2003

Ann Nutr Metab

174

113

View full text Add to dashboard Cite

show abstract

“…This finding is similar to observations in older children and adults (7,37). Animal studies have suggested that 1,25(OH)2 vitamin D and 25-OH vitamin D are better absorbed than vitamin D in the absence of bile salts (38,39).…”

Section: -Oh Vitamin Dsupporting

confidence: 87%

Bone Disease in Chronic Childhood Cholestasis II. Better Absorption of 25-OH Vitamin D than Vitamin D in Extrahepatic Biliary Atresia

1990

View full text Add to dashboard Cite

ABSTRACT. Infants with extrahepatic biliary atresia (EHBA) commonly develop rickets in infancy, whereas long-term survivors with EHBA commonly develop osteopenia with increasing age. We evaluated baseline vitamin D (Dz and D3), 25-OH vitamin D2 and D,, 1,25(0H)2 vitamin D, bone mineral content, and vitamin D2 and 25-OH vitamin D3 absorption in six infants and children (age 4-22 mo) with EHBA whose portoenterostomy failed to produce bile flow (group 1) and five infants and children (age 10112 to 8-4/12 y) with EHBA whose portoenterostomy repair led to good postoperative bile flow (group 2). Baseline serum vitamin Dz and DJ were undetectable in all subjects in group 1 despite supplements of 2500-5000 IU/ day, whereas all group 2 subjects given supplements (doses 400-5000 IU/d) had measurable levels. Baseline serum 25-OH vitamin D was less than 15 ng/mL in five of six (three with rickets) in group 1, whereas only one in group 2 had concentrations less than 15 ng/mL. A significantly blunted rise of vitamin D2 above baseline and reduced area under the absorption curve after 1000 IU/kg vitamin DZ were found in group 1 patients compared to group 2 (both p < 0.01), and five pediatric controls (both p < 0.01). The peak change and area under the absorption curve for serum 25-OH vitamin D3 from baseline after 10 pg/kg 25-OH vitamin D3 were significantly reduced for group 1 (both at least p < 0.05) and group 2 compared to controls (both p < 0.05). Malabsorption of supplemental doses of vitamin D compromises their efficacy to prevent rickets in infants with EHBA with poor bile flow after portoenterostomy. Despite severe malabsorption of vitamin D, we suggest that oral 25-OH vitamin D may be absorbed sufficiently to prevent rickets. (Pediatr Res 27:26-31, 1990) Abbreviations EHBA, extrahepatic biliary atresia PTH, parathyroid hormone EHBA accounts for approximately 25% of cases of neonatal cholestasis (1). Operable forms with atresia limited to the distal portions of the biliary tract account for 10-15% of the cases. In

show abstract

“…Several studies have suggested that the more polar hydroxylated vitamin D preparations (25-OHD and 1,25-OHD) are better absorbed than ergocalciferol and may be a better supplement option (31,32). Unfortunately, the only single-ingredient product containing 25-OHD was removed from the market by the manufacturer in 2001, leaving none currently available in the United States.…”

Section: Discussionmentioning

confidence: 99%

Failure of High-Dose Ergocalciferol to Correct Vitamin D Deficiency in Adults with Cystic Fibrosis

Boyle

Noschese

Watts

et al. 2005

Am J Respir Crit Care Med

View full text Add to dashboard Cite

Survival has steadily improved in cystic fibrosis (CF) over the last few decades, with the median survival age now older than 33 years, and over 40% of all individuals with CF older than 18 years (1). With this increase in survival, there has also been growing recognition of health issues unique to the adult population with CF (2). One of these issues is bone health, because studies using dual-energy x-ray absorptiometry measurements of bone density have determined that, despite their young age, approximately 20 to 25% of adults with CF have osteoporosis and another 40% have osteopenia (3-5). The etiology of this bone disease is multifactorial, with contributors including fat malabsorption (resulting in vitamin D malabsorption and abnormal calcium metabolism) (6-8), glucocorticoid therapy (9, 10), poor nutritional status (11), inadequate gonadal hormones (10, 12), and elevated circulating cytokines (13). Recognition of this increased risk of osteoporosis in CF has led to greater efforts to optimize vitamin D status and calcium absorption (4,14). The overall prevalence of vitamin D deficiency in adults with CF is strikingly high, with as many as 50 to 60% having 25-hydroxyvitamin D (25-OHD) levels below 20 ng/ml (5, 15). Data demonstrating that serum 25-OHD levels need to exceed 30 ng/ml to prevent a rise in serum parathyroid hormone (16) suggest that the prevalence of vitamin D deficiency in CF may be even higher.Because of the growing concern about bone disease in CF, the U.S. Cystic Fibrosis Foundation (CFF) convened a panel of experts to develop consensus treatment guidelines to optimize CF bone health, and these recommendations were recently published (17). The guidelines contained several specific recommendations regarding vitamin D. First, greater attention to maintaining adequate serum 25-OHD levels should occur, with levels being checked annually in the late fall with the goal of maintaining serum 25-OHD between 30 and 60 ng/ml (75-150 nmol/L). Second, all individuals with CF who are older than 1 year should receive 800 IU/day of oral ergocalciferol (vitamin D 2 ). Failure of this supplementation to maintain serum 25-OHD levels above 30 ng/ml should lead to aggressive repletion with high-dose oral ergocalciferol. The guidelines recommended a stepped approach for repletion, with an initial regimen of 50,000 IU/week of oral ergocalciferol for 8 weeks. Failure of this regimen to raise serum 25-OHD to over 30 ng/ml should lead to a second course of oral ergocalciferol with 50,000 IU/twice weekly for 8 weeks. Persistence of serum 25-OHD levels below 30 ng/ml despite these supplemental regimens should result in consideration of alternative modes of therapy, such as calcitriol or phototherapy. This treatment protocol was developed on the basis of data in individuals without CF, but was recognized as a "first step" in addressing the clear need for more aggressive vitamin D therapy in individuals with CF. Conference leaders stated a need for CF-specific data in the future on which to determine optimal dosing rec...

show abstract

Intestinal absorption of cholecalciferol and 25-hydroxycholecalciferol in chronic cholestatic liver disease

Cited by 51 publications

References 24 publications

Food Contents and Biological Activity of 25-Hydroxyvitamin D: A Vitamin D Metabolite to Be Reckoned With?

Food Contents and Biological Activity of 25-Hydroxyvitamin D: A Vitamin D Metabolite to Be Reckoned With?

Bone Disease in Chronic Childhood Cholestasis II. Better Absorption of 25-OH Vitamin D than Vitamin D in Extrahepatic Biliary Atresia

Failure of High-Dose Ergocalciferol to Correct Vitamin D Deficiency in Adults with Cystic Fibrosis

Contact Info

Product

Resources

About